Bispecific Antibodies
The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed more than 25 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. A...
Συγγραφή απο Οργανισμό/Αρχή: | SpringerLink (Online service) |
---|---|
Άλλοι συγγραφείς: | Kontermann, Roland E. (Επιμελητής έκδοσης) |
Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
Γλώσσα: | English |
Έκδοση: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
2011.
|
Θέματα: | |
Διαθέσιμο Online: | Full Text via HEAL-Link |
Παρόμοια τεκμήρια
-
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
Έκδοση: (2017) -
Antibody-Drug Conjugates and Immunotoxins From Pre-Clinical Development to Therapeutic Applications /
Έκδοση: (2013) -
Resistance to Immunotherapeutic Antibodies in Cancer Strategies to Overcome Resistance /
Έκδοση: (2013) -
Metastasis of Colorectal Cancer
Έκδοση: (2010) -
Drugs for HER-2-positive Breast Cancer
Έκδοση: (2011)